uniQure
Leena Dalal currently serves as Vice President of New Product Planning (Commercialization Strategy) at uniQure, focusing on the launch of an investigational product for Huntington's Disease. Previous experience includes serving as Vice President of Commercialization Strategy for pipeline products at Sage Therapeutics, with a focus on neurodegenerative diseases. At Alnylam Pharmaceuticals, Leena was the US Brand Lead and Launch Lead for the TTR Amyloidosis Franchise, successfully launching ONPATTRO for hATTR amyloidosis. Earlier roles included key marketing positions at Shire, Cubist Pharmaceuticals, Vertex Pharmaceuticals, Novartis, and Sanofi Pasteur, demonstrating a robust background in product launches across various therapeutic areas. Leena holds an MBA from Boston University and completed the General Management Program at Harvard Business School, alongside a Bachelor's degree in Pharmacy.
This person is not in any teams
This person is not in any offices
uniQure
2 followers
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.